Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Polyrizon Ltd., a pharmaceutical company specializing in preparations, has announced it will hold its Annual General Meeting (AGM) of Shareholders on Thursday, April 17, 2025. The meeting is scheduled for 16:00 p.m. Israel time at the company’s headquarters in Raanana, Israel. The announcement comes as the company’s stock shows strong momentum, with a 37% gain over the past six months, according to InvestingPro data.
The announcement made today includes details that shareholders will have the option to vote via proxy without attending in person, with relevant documents provided as exhibits to the SEC filing. These documents, referred to as Exhibit 99.1 and Exhibit 99.2, contain the Notice and Proxy Card respectively. The meeting precedes the company’s next earnings report, scheduled for April 28, where analysts expect Polyrizon to demonstrate profitability for the current fiscal year.
The SEC filing, a standard Form 6-K, serves as a report of foreign private issuers to the U.S. Securities and Exchange Commission. This particular filing by Polyrizon also includes an incorporation by reference into the company’s existing Registration Statement on Form S-8 (File No. 333-284410), ensuring that the information in this report is considered part of that document from the date of submission.
This information is based on a press release statement and is intended to inform shareholders and the public of the upcoming AGM and the mechanisms in place for shareholder voting. The filing was signed by Tomer Izraeli, the Chief Executive Officer of Polyrizon Ltd., and filed today.
Polyrizon’s business address is listed as 5 Ha-Tidhar Street, Raanana, 4366507, Israel, and the company is incorporated under the laws of Israel. It operates within the pharmaceutical industry under the SIC code 2834 for pharmaceutical preparations.
Shareholders of Polyrizon Ltd. and interested parties are encouraged to review the proxy materials provided by the company to understand the matters to be voted on at the upcoming AGM. InvestingPro analysis suggests the company is currently undervalued, with 12 additional key insights available to subscribers, including detailed financial health metrics and growth indicators.
In other recent news, Polyrizon Ltd. has announced the appointment of Liron Carmel to its Board of Directors, effective immediately. This decision was approved by the Board of Directors and disclosed in a filing with the Securities and Exchange Commission. Mr. Carmel, who previously served on the board, brings extensive experience from his roles in various industries, including biopharma, technology, and financial services. Currently, he is the CEO of Xylo Technologies Ltd. and has held positions such as CEO and director of CannaPowder and director for Chiron Refineries Ltd. and Gix. His diverse background is expected to enhance Polyrizon’s leadership as the company continues its endeavors in the pharmaceutical preparations industry. The appointment is part of Polyrizon’s ongoing strategy to strengthen its governance and executive team. This update was included in the latest 6-K form submitted by Polyrizon to the SEC, providing investors with the latest developments in the company’s governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.